Due to its low MIC against aerobic bacteria, GPB, and Gram-negative bacteria (GNB), delafloxacin provides an important supplement for the treatment of acute bacterial skin infections and a wide variety of bacterial infections, particularly drug-resistant bacterial infections. Here, GYPB is linked to bacterial infectious disease.